7 Simple Tricks To Rocking Your Personalized Depression Treatment > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapy and medication isn't effective. Personalized treatment could be the answer.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into customized micro-interventions to improve mental health. We examined the most effective-fitting personalized ML models for each individual, using Shapley values to determine their characteristic predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

Depression is among the most prevalent causes of mental illness.1 However, only about half of people suffering from the condition receive treatment1. To improve outcomes, clinicians must be able to identify and treat patients who are the most likely to respond to specific treatments.

A customized depression treatment plan can aid. Utilizing sensors on mobile phones, an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to predict which patients will benefit from which treatments. Two grants totaling more than $10 million will be used to discover biological and behavior predictors of response.

So far, the majority of research on predictors for depression treatment exercise treatment effectiveness has focused on sociodemographic and clinical characteristics. These include demographic factors such as age, sex and education, clinical characteristics such as symptoms severity and comorbidities and biological markers such as neuroimaging and genetic variation.

While many of these factors can be predicted by the information available in medical records, very few studies have used longitudinal data to study the factors that influence mood in people. Few also take into account the fact that mood varies significantly between individuals. It is therefore important to devise methods that allow for the identification and quantification of personal differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can identify distinct patterns of behavior and emotions that vary between individuals.

In addition to these methods, the team developed a machine-learning algorithm to model the changing variables that influence each person's mood. The algorithm combines these individual differences into a unique "digital phenotype" for each participant.

This digital phenotype has been linked to CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was weak however (Pearson r = 0,08; P-value adjusted for BH = 3.55 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is the most common reason for disability across the world, but it is often untreated and misdiagnosed. Depression disorders are usually not treated due to the stigma associated with them and the lack of effective treatments.

To facilitate personalized treatment in order to provide a more personalized treatment, identifying patterns that can predict symptoms is essential. However, the methods used to predict symptoms depend on the clinical interview which has poor reliability and only detects a small variety of characteristics associated with depression treatment tms.2

Machine learning can enhance the accuracy of the diagnosis and treatment of depression by combining continuous digital behavior phenotypes gathered from smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements. They also capture a wide range of distinctive behaviors and activity patterns that are difficult to record using interviews.

The study involved University of California Los Angeles (UCLA) students who were suffering from mild to severe depressive symptoms participating in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical treatment in accordance with their severity of depression. Those with a CAT-DI score of 35 65 students were assigned online support with an instructor and those with a score 75 patients were referred for psychotherapy in-person.

Participants were asked a series questions at the beginning of the study regarding their demographics and psychosocial traits. The questions asked included education, age, sex and gender as well as marital status, financial status as well as whether they divorced or not, current suicidal ideas, intent or attempts, and how often they drank. The CAT-DI was used to rate the severity of depression symptoms on a scale ranging from 100 to. The CAT DI assessment was conducted every two weeks for participants who received online support, and weekly for those who received in-person assistance.

Predictors of Treatment Response

Research is focused on individualized depression holistic treatment for anxiety and depression. Many studies are aimed at identifying predictors, which will help clinicians identify the most effective drugs to treat each patient. Pharmacogenetics in particular identifies genetic variations that determine how the human body metabolizes drugs. This lets doctors choose the medications that are likely to be the most effective for every patient, minimizing the time and effort needed for trial-and-error treatments and avoiding any side negative effects.

Another promising method is to construct models of prediction using a variety of data sources, combining data from clinical studies and neural imaging data. These models can be used to determine the best combination of variables predictive of a particular outcome, such as whether or not a drug will improve symptoms and mood. These models can be used to predict the patient's response to a treatment, allowing doctors maximize the effectiveness.

A new generation employs machine learning techniques like the supervised and classification algorithms, regularized logistic regression and tree-based methods to combine the effects of multiple variables and increase the accuracy of predictions. These models have been shown to be useful in predicting treatment outcomes, such as response to antidepressants. These methods are becoming more popular in psychiatry and could be the norm in future treatment.

In addition to prediction models based on ML, research into the mechanisms that cause depression continues. Recent research suggests that the disorder is linked with dysfunctions in specific neural circuits. This theory suggests that an individualized treatment for depression will be based upon targeted therapies that restore normal function to these circuits.

Internet-based-based therapies can be an option to accomplish this. They can provide a more tailored and individualized experience for patients. One study found that a program on the internet was more effective than standard care in alleviating symptoms and ensuring the best quality of life for patients suffering from MDD. Additionally, a randomized controlled study of a customized treatment for depression And anxiety for depression demonstrated an improvement in symptoms and fewer side effects in a significant percentage of participants.

Predictors of adverse effects

A major issue in personalizing depression treatment is predicting the antidepressant medications that will have very little or no side effects. Many patients experience a trial-and-error method, involving various medications prescribed until they find one that is safe and effective. Pharmacogenetics provides a novel and exciting method to choose antidepressant medications that is more effective and specific.

A variety of predictors are available to determine the best antidepressant to prescribe, such as gene variants, patient phenotypes (e.g. gender, sex or ethnicity) and the presence of comorbidities. To determine the most reliable and accurate predictors for a particular treatment, random controlled trials with larger numbers of participants will be required. This is due to the fact that it can be more difficult to determine the effects of moderators or interactions in trials that only include one episode per participant instead of multiple episodes spread over a period of time.

Furthermore the prediction of a patient's response will likely require information about the severity of symptoms, comorbidities and the patient's own experience of tolerability and effectiveness. At present, only a few easily identifiable sociodemographic and clinical variables are believed to be reliably associated with the severity of MDD like gender, age race/ethnicity, BMI, the presence of alexithymia and the severity of depressive symptoms.

The application of pharmacogenetics to depression treatment is still in its infancy and there are many obstacles to overcome. First, it is important to be able to comprehend and understand the definition of the genetic factors that cause depression, and an understanding of a reliable predictor of treatment response. Additionally, ethical issues like privacy and the appropriate use of personal genetic information must be considered carefully. In the long-term, pharmacogenetics may be a way to lessen the stigma that surrounds mental health care and improve the outcomes of those suffering with depression. Like any other psychiatric treatment it is crucial to give careful consideration and implement the plan. For now, the best course of action is to provide patients with an array of effective medications for depression and encourage them to speak freely with their doctors about their experiences and concerns.